Scpharmaceuticals Net Income Per Share vs Ptb Ratio Analysis

SCPH Stock

USD 3.45 0.16 4.86%

Scpharmaceuticals financial indicator trend analysis is much more than just breaking down Scpharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Scpharmaceuticals is a good investment. Please check the relationship between Scpharmaceuticals Net Income Per Share and its Ptb Ratio accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.

Net Income Per Share vs Ptb Ratio

Net Income Per Share vs Ptb Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Scpharmaceuticals Net Income Per Share account and Ptb Ratio. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Scpharmaceuticals' Net Income Per Share and Ptb Ratio is -0.23. Overlapping area represents the amount of variation of Net Income Per Share that can explain the historical movement of Ptb Ratio in the same time period over historical financial statements of Scpharmaceuticals, assuming nothing else is changed. The correlation between historical values of Scpharmaceuticals' Net Income Per Share and Ptb Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income Per Share of Scpharmaceuticals are associated (or correlated) with its Ptb Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ptb Ratio has no effect on the direction of Net Income Per Share i.e., Scpharmaceuticals' Net Income Per Share and Ptb Ratio go up and down completely randomly.

Correlation Coefficient

-0.23

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Net Income Per Share

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Most indicators from Scpharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Scpharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.As of now, Scpharmaceuticals' Selling General Administrative is increasing as compared to previous years. The Scpharmaceuticals' current Issuance Of Capital Stock is estimated to increase to about 74.6 M, while Sales General And Administrative To Revenue is projected to decrease to 3.14.

	2022	2023	2024	2025 (projected)
Interest Expense	3.3M	8.1M	9.3M	9.8M
Depreciation And Amortization	468K	626K	719.9K	502.9K

Interest Expense Depreciation And Amortization

Scpharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets
Total Assets		0.51	0.73	-0.21	0.54	0.95	0.84	-0.65	-0.8	0.53	0.92	0.88	0.82	0.47	0.99	0.63	0.58	0.19	0.92	0.46	0.64	0.69	0.35	0.64	0.91	1.0
Other Current Liab	0.51		0.72	0.1	0.9	0.44	0.41	0.24	-0.87	0.93	0.26	0.41	0.26	0.0	0.44	0.96	0.83	0.49	0.68	0.92	0.92	0.89	0.62	0.73	0.45	0.51
Total Current Liabilities	0.73	0.72		-0.19	0.61	0.74	0.6	-0.25	-0.89	0.62	0.57	0.62	0.62	0.27	0.68	0.82	0.88	0.23	0.9	0.61	0.87	0.84	0.45	0.66	0.75	0.73
Total Stockholder Equity	-0.21	0.1	-0.19		0.12	-0.15	0.17	0.28	0.19	0.4	-0.24	0.06	-0.51	-0.58	-0.25	0.11	-0.22	0.09	-0.27	0.39	-0.09	-0.1	0.04	0.01	-0.27	-0.22
Other Liab	0.54	0.9	0.61	0.12		0.46	0.42	0.27	-0.84	0.88	0.23	0.41	0.32	-0.17	0.48	0.9	0.76	0.52	0.67	0.87	0.84	0.87	0.62	0.72	0.4	0.55
Net Tangible Assets	0.95	0.44	0.74	-0.15	0.46		0.9	-0.65	-0.75	0.46	0.89	0.93	0.82	0.47	0.94	0.59	0.56	-0.08	0.91	0.45	0.61	0.64	0.1	0.64	0.8	0.95
Property Plant And Equipment Net	0.84	0.41	0.6	0.17	0.42	0.9		-0.58	-0.61	0.53	0.8	0.99	0.59	0.24	0.82	0.51	0.45	0.0	0.76	0.56	0.43	0.44	0.15	0.72	0.76	0.84
Net Debt	-0.65	0.24	-0.25	0.28	0.27	-0.65	-0.58		0.13	0.16	-0.86	-0.64	-0.65	-0.66	-0.71	0.08	0.09	0.24	-0.4	0.24	0.03	-0.01	0.16	-0.08	-0.66	-0.65
Retained Earnings	-0.8	-0.87	-0.89	0.19	-0.84	-0.75	-0.61	0.13		-0.77	-0.57	-0.64	-0.64	-0.23	-0.75	-0.91	-0.89	-0.35	-0.93	-0.76	-0.93	-0.94	-0.54	-0.78	-0.72	-0.8
Accounts Payable	0.53	0.93	0.62	0.4	0.88	0.46	0.53	0.16	-0.77		0.31	0.5	0.15	-0.11	0.46	0.92	0.67	0.53	0.6	0.96	0.81	0.8	0.63	0.7	0.45	0.53
Cash	0.92	0.26	0.57	-0.24	0.23	0.89	0.8	-0.86	-0.57	0.31		0.85	0.82	0.61	0.95	0.4	0.29	-0.04	0.74	0.23	0.43	0.46	0.1	0.48	0.85	0.92
Non Current Assets Total	0.88	0.41	0.62	0.06	0.41	0.93	0.99	-0.64	-0.64	0.5	0.85		0.67	0.32	0.86	0.51	0.46	-0.03	0.8	0.52	0.46	0.47	0.13	0.72	0.8	0.88
Non Currrent Assets Other	0.82	0.26	0.62	-0.51	0.32	0.82	0.59	-0.65	-0.64	0.15	0.82	0.67		0.43	0.85	0.4	0.4	-0.15	0.76	0.16	0.49	0.53	0.01	0.51	0.72	0.82
Other Assets	0.47	0.0	0.27	-0.58	-0.17	0.47	0.24	-0.66	-0.23	-0.11	0.61	0.32	0.43		0.51	0.06	0.16	-0.23	0.4	-0.24	0.21	0.21	-0.15	-0.07	0.42	0.47
Cash And Short Term Investments	0.99	0.44	0.68	-0.25	0.48	0.94	0.82	-0.71	-0.75	0.46	0.95	0.86	0.85	0.51		0.57	0.5	0.14	0.88	0.38	0.59	0.64	0.3	0.59	0.9	0.99
Net Receivables	0.63	0.96	0.82	0.11	0.9	0.59	0.51	0.08	-0.91	0.92	0.4	0.51	0.4	0.06	0.57		0.83	0.39	0.77	0.89	0.97	0.96	0.55	0.73	0.52	0.63
Common Stock Shares Outstanding	0.58	0.83	0.88	-0.22	0.76	0.56	0.45	0.09	-0.89	0.67	0.29	0.46	0.4	0.16	0.5	0.83		0.4	0.83	0.7	0.86	0.84	0.58	0.7	0.59	0.58
Non Current Liabilities Total	0.19	0.49	0.23	0.09	0.52	-0.08	0.0	0.24	-0.35	0.53	-0.04	-0.03	-0.15	-0.23	0.14	0.39	0.4		0.2	0.41	0.32	0.35	0.97	0.21	0.37	0.19
Capital Surpluse	0.92	0.68	0.9	-0.27	0.67	0.91	0.76	-0.4	-0.93	0.6	0.74	0.8	0.76	0.4	0.88	0.77	0.83	0.2		0.58	0.8	0.83	0.4	0.72	0.84	0.92
Inventory	0.46	0.92	0.61	0.39	0.87	0.45	0.56	0.24	-0.76	0.96	0.23	0.52	0.16	-0.24	0.38	0.89	0.7	0.41	0.58		0.77	0.74	0.52	0.82	0.38	0.46
Other Current Assets	0.64	0.92	0.87	-0.09	0.84	0.61	0.43	0.03	-0.93	0.81	0.43	0.46	0.49	0.21	0.59	0.97	0.86	0.32	0.8	0.77		0.99	0.5	0.65	0.54	0.64
Other Stockholder Equity	0.69	0.89	0.84	-0.1	0.87	0.64	0.44	-0.01	-0.94	0.8	0.46	0.47	0.53	0.21	0.64	0.96	0.84	0.35	0.83	0.74	0.99		0.52	0.62	0.56	0.69
Total Liab	0.35	0.62	0.45	0.04	0.62	0.1	0.15	0.16	-0.54	0.63	0.1	0.13	0.01	-0.15	0.3	0.55	0.58	0.97	0.4	0.52	0.5	0.52		0.35	0.52	0.35
Property Plant And Equipment Gross	0.64	0.73	0.66	0.01	0.72	0.64	0.72	-0.08	-0.78	0.7	0.48	0.72	0.51	-0.07	0.59	0.73	0.7	0.21	0.72	0.82	0.65	0.62	0.35		0.6	0.64
Preferred Stock Total Equity	0.91	0.45	0.75	-0.27	0.4	0.8	0.76	-0.66	-0.72	0.45	0.85	0.8	0.72	0.42	0.9	0.52	0.59	0.37	0.84	0.38	0.54	0.56	0.52	0.6		0.91
Total Current Assets	1.0	0.51	0.73	-0.22	0.55	0.95	0.84	-0.65	-0.8	0.53	0.92	0.88	0.82	0.47	0.99	0.63	0.58	0.19	0.92	0.46	0.64	0.69	0.35	0.64	0.91

Click cells to compare fundamentals

Scpharmaceuticals Account Relationship Matchups

Scpharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	109.0M	79.0M	124.2M	94.5M	108.7M	90.6M
Other Current Liab	4.3M	3.5M	4.7M	8.7M	10.0M	10.5M
Total Current Liabilities	9.3M	14.8M	7.4M	13.1M	15.1M	8.3M
Total Stockholder Equity	(161.7M)	(189.7M)	(226.5M)	37.2M	33.5M	35.2M
Other Liab	58K	219K	367K	7.5M	8.7M	9.1M
Net Tangible Assets	51.4M	82.2M	63.1M	72.4M	83.3M	54.8M
Property Plant And Equipment Net	908K	479K	620K	1.5M	1.7M	1.0M
Net Debt	(85.1M)	(56.6M)	(33.7M)	(6.5M)	(7.5M)	(7.9M)
Retained Earnings	(161.7M)	(189.7M)	(226.5M)	(281.3M)	(253.2M)	(240.6M)
Accounts Payable	1.7M	544K	1.5M	4.0M	4.6M	4.8M
Cash	105.3M	74.3M	71.1M	46.8M	53.8M	75.7M
Non Current Assets Total	1.2M	762K	887K	1.5M	1.8M	1.2M
Non Currrent Assets Other	132K	283K	267K	82K	94.3K	159.4K
Other Assets	1.1M	283K	267K	1.0	1.15	1.09
Cash And Short Term Investments	105.3M	75.5M	118.4M	76.0M	87.4M	85.2M
Net Receivables	479K	310K	2.3M	4.5M	5.2M	5.4M
Common Stock Shares Outstanding	24.6M	27.4M	28.4M	38.5M	44.3M	22.2M
Liabilities And Stockholders Equity	(134.8M)	(167.1M)	(174.8M)	94.5M	85.0M	89.3M
Non Current Liabilities Total	17.6M	7.7M	44.3M	44.1M	50.7M	29.9M
Capital Surpluse	180.8M	243.8M	246.2M	298.9M	343.8M	182.1M
Other Current Assets	2.7M	3.0M	2.5M	3.6M	4.1M	4.3M
Other Stockholder Equity	243.8M	246.2M	298.9M	318.6M	366.3M	384.7M
Total Liab	26.9M	22.6M	51.8M	57.3M	65.9M	38.2M
Property Plant And Equipment Gross	93K	649K	808K	1.5M	1.7M	1.8M
Total Current Assets	107.8M	78.3M	123.3M	92.9M	106.9M	89.4M
Accumulated Other Comprehensive Income	(102K)	1K	(1K)	32K	(1.2K)	(1.2K)
Property Plant Equipment	1.3M	908K	69K	54K	48.6K	46.2K
Non Current Liabilities Other	219K	367K	35K	177K	203.6K	147.7K
Short Long Term Debt Total	20.2M	17.6M	37.4M	40.3M	46.3M	24.9M
Long Term Debt	16.9M	7.4M	36.8M	38.8M	44.6M	46.9M
Long Term Debt Total	18.9M	16.9M	7.4M	36.8M	42.3M	44.4M
Capital Lease Obligations	940K	476K	574K	1.5M	1.3M	963.3K
Net Invested Capital	101.4M	73.6M	109.2M	76.0M	68.4M	72.5M
Net Working Capital	98.5M	63.4M	115.9M	79.8M	71.8M	71.8M
Short Term Debt	3.3M	10.8M	1.1M	352K	404.8K	384.6K

Currently Active Assets on Macroaxis

F	Ford Motor
GM	General Motors
S	SentinelOne
GOOG	Alphabet Inc Class C
WD	Walker Dunlop

When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:

How To Invest In Scpharmaceuticals

Details

Is Scpharmaceuticals Stock a good investment?

Details

What is Scpharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.

You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.95)

Revenue Per Share

0.741

Quarterly Revenue Growth

1.641

Return On Assets

(0.42)

Return On Equity

(1.67)

The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Scpharmaceuticals Net Income Per Share vs Ptb Ratio Analysis

Net Income Per Share vs Ptb Ratio

Net Income Per Share vs Ptb Ratio Correlation Analysis

Correlation Coefficient

Net Income Per Share

Ptb Ratio

Scpharmaceuticals fundamental ratios Correlations

Scpharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Scpharmaceuticals fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Cash And Short Term Investments
Other Stockholder Equity	+ 0.99	Other Current Assets
Other Current Assets	+ 0.97	Net Receivables

Other Stockholder Equity	- 0.94	Retained Earnings
Other Current Assets	- 0.93	Retained Earnings
Capital Surpluse	- 0.93	Retained Earnings
Net Receivables	- 0.91	Retained Earnings
Common Stock Shares Outstanding	- 0.89	Retained Earnings
Retained Earnings	- 0.89	Total Current Liabilities